Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma

Leuk Lymphoma. 2018 May;59(5):1271-1273. doi: 10.1080/10428194.2017.1372575. Epub 2017 Sep 11.
No abstract available

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Melphalan / administration & dosage
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Panobinostat / administration & dosage
  • Prednisone / administration & dosage
  • Prognosis
  • Survival Rate
  • Thalidomide / administration & dosage

Substances

  • Thalidomide
  • Panobinostat
  • Melphalan
  • Prednisone